News
PYPD
4.420
-4.33%
-0.200
Craig-Hallum Reaffirms Their Buy Rating on PolyPid (PYPD)
TipRanks · 1h ago
PolyPid Earnings Call Flags Big 2026 Catalyst
TipRanks · 16h ago
Polypid targets rolling NDA submission for D-PLEX100 by end of Q1 2026 amid advanced U.S. partnership talks
Seeking Alpha · 20h ago
PolyPid Price Target Maintained With a $13.00/Share by HC Wainwright & Co.
Dow Jones · 21h ago
HC Wainwright & Co. Reiterates Buy on PolyPid, Maintains $13 Price Target
Benzinga · 22h ago
PolyPid: Advancing D-PLEX100 De-Risks Platform Potential and Creates Compelling Buy-Rated Risk-Reward
TipRanks · 1d ago
Israel's PolyPid Q4 EPS improves on lower R&D expenses 
Reuters · 1d ago
PolyPid GAAP EPS of -$0.41 misses by $0.08
Seeking Alpha · 1d ago
PolyPid posts FY2025 net loss of USD 8.47 million
Reuters · 1d ago
PolyPid Q4 EPS $(0.41) Misses $(0.34) Estimate.
Benzinga · 1d ago
Earnings Scheduled For February 11, 2026
Benzinga · 1d ago
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results
Barchart · 1d ago
Preview: PolyPid's Earnings
Benzinga · 1d ago
Weekly Report: what happened at PYPD last week (0202-0206)?
Weekly Report · 3d ago
PolyPid Ltd. Held Extraordinary General Meeting of Shareholders
Reuters · 02/04 21:09
Weekly Report: what happened at PYPD last week (0126-0130)?
Weekly Report · 02/02 09:57
PolyPid Ltd. to Report Fourth Quarter 2025 Financial Results and Operational Highlights
Reuters · 01/28 13:00
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 01/26 12:05
Weekly Report: what happened at PYPD last week (0119-0123)?
Weekly Report · 01/26 09:57
Ten new option listings and two option delistings on January 22nd
TipRanks · 01/22 13:36
More
Webull provides a variety of real-time PYPD stock news. You can receive the latest news about Polypid Ltd. through multiple platforms. This information may help you make smarter investment decisions.
About PYPD
Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.